Vasculitis & polymyalgia rheumatica
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A 1c During the Treatment of Giant Cell Arteritis
Authors' conclusion
Tocilizumab treatment was associated with a substantial reduction in HbA1c level, independent of glucocorticoid exposure, which may be achieved through a combination of glycemic and nonglycemic effects.
Study context
- Population
- Giant cell arteritis (GCA) patients with complete data from GiACTA, with and without diabetes mellitus at baseline, during GC taperingpatients with complete data
- Participants
- 209 patients
- Comparison
- Tocilizumab plus GC vs GC only
- Primary endpoint
- Change in HbA1c level
- Follow-up
- 52 weeks
Methodological detailsmultivariable mixed-effects model
- Multivariable mixed-effects model
Primary result
As reported in the abstract
Median HbA1c decrease
β
−0.209 %
P < 0.01
those without diabetes
β
−0.290 %
P = 0.23
those with diabetes
Tocilizumab/glucocorticoid
0.50%
median
Glucocorticoid-only
0.10%
median
Further findings
Improvement from prediabetes to normal glucose tolerance
Association of daily GC dose with HbA1c
- Baseline diabetes: β per mg (P < 0.01)
- 0.018%/mg
- No baseline diabetes: β per mg (P < 0.01)
- 0.005%/mg
Original publication
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A 1c During the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →